Daiichi Sankyo Co., Ltd.
↗Tokyo, Japan
Daiichi Sankyo is a global, research-oriented pharmaceutical company headquartered in Tokyo, Japan. With over 120 years of history, the company has undergone a strategic pivot to become a leader in oncology, particularly through its proprietary antibody-drug conjugate (ADC) technology platform.
Beyond oncology, the company maintains a strong portfolio in cardiovascular and specialty medicines. It operates globally with a focus on creating innovative pharmaceuticals that address high unmet medical needs, leveraging a multi-modality approach that includes small molecules, ADCs, nucleic acid drugs, and gene therapies.
CLASSIFICATION
SIZE & FINANCIALS
Employees:10000+
Revenue:1.886T JPY (FY2024)
Founded:2005
Ownership:public
Status:operating
STOCK
Exchange:TSE
Ticker:4568
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (Enhertu)
Modalities:Antibody-Drug Conjugates (ADC), Small molecule, mAb, Nucleic acid drugs, Gene therapy, Cell therapy
Trial Phases:-
CORPORATE STRUCTURE
Subsidiaries:Daiichi Sankyo, Inc. (US), Daiichi Sankyo Europe GmbH, Shanghai Daiichi Sankyo Pharmaceutical Co., Ltd.
Key Partnerships:AstraZeneca (Enhertu collaboration), Merck & Co. (ADC co-development/co-commercialization)
COMPETITION
Position:Leader
Competitors:Seagen, GSK, BioNTech, Duality Biologics, Medilink Therapeutics
LEADERSHIP
Key Executives:
Ken Keller - President and CEO, Daiichi Sankyo, Inc. (US)
LINKS
Website:daiichi-sankyo.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Daiichi Sankyo Co., Ltd. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Daiichi Sankyo Co., Ltd.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.